Identify and characterise diabetes towards limiting its progression.

Trial Profile

Identify and characterise diabetes towards limiting its progression.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Peptide p277 (Primary)
  • Indications Latent autoimmune diabetes in adults
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTION-LADA
  • Most Recent Events

    • 06 Mar 2012 Planned end date changed from 1 Sep 2012 to 1 Mar 2012 as reported by UKCRN.
    • 06 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
    • 02 Oct 2011 Planned end date changed from 31 Dec 2010 to 1 Sep 2012 as reported by UKCRN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top